Cargando…

Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial

AIMS: Although the effect of the angiotensin receptor blocker neprilysin inhibitor (ARNI) sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been evaluated, its effects on functional capacity in patients with HF and ejection fraction (EF) >40% has yet to be d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wachter, Rolf, Shah, Sanjiv J., Cowie, Martin R., Szecsödy, Peter, Shi, Victor, Ibram, Ghionul, Zhao, Ziqiang, Gong, Jianjian, Klebs, Sven, Pieske, Burkert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Study Designs
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261527/ https://www.ncbi.nlm.nih.gov/pubmed/32297449 http://dx.doi.org/10.1002/ehf2.12694

Ejemplares similares

Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2021)

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
por: McMurray, John J. V., et al.
Publicado: (2013)

Design of the Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor Versus Placebo in Patients With Congenital Systemic Right Ventricle Heart Failure (PARACYS-RV) Trial
por: Chaix, Marie-A., et al.
Publicado: (2023)

German Cardiac Arrest Registry: rationale and design of G-CAR
por: Pöss, Janine, et al.
Publicado: (2022)

Rationale and design of the CardioMEMS Post‐Market Multinational Clinical Study: COAST
por: Cowie, Martin R., et al.
Publicado: (2020)

Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C
por: Reddy, K Rajender, et al.
Publicado: (2012)

Rationale and design of the EMPYREAN study
por: Motoki, Hirohiko, et al.
Publicado: (2020)

Rationale and design of the SERVE-HF study: treatment of sleep-disordered breathing with predominant central sleep apnoea with adaptive servo-ventilation in patients with chronic heart failure
por: Cowie, Martin R., et al.
Publicado: (2013)

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
por: Solomon, Scott D., et al.
Publicado: (2021)

Rationale and design of the AUGUST‐AHF Study
por: Zhang, Jingjing, et al.
Publicado: (2020)

Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy
por: Ghazi, Lama, et al.
Publicado: (2017)

Mechanisms of Diuretic Resistance Study: design and rationale
por: Cox, Zachary L., et al.
Publicado: (2020)

Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration
por: Pitcher, Alex, et al.
Publicado: (2015)

Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
por: Hundertmark, Moritz J., et al.
Publicado: (2021)

Rationale and Design of the PRegnancy and Infant DEvelopment (PRIDE) Study
por: van Gelder, Marleen M H J, et al.
Publicado: (2013)

The genomics of heart failure: design and rationale of the HERMES consortium
por: Lumbers, R. Thomas, et al.
Publicado: (2021)

Kyoto Congestive Heart Failure (KCHF) study: rationale and design
por: Yamamoto, Erika, et al.
Publicado: (2017)

Rate or Rhythm Control in CRT (RHYTHMIC): Study rationale and protocol
por: Elliott, Mark K., et al.
Publicado: (2022)

RAAS-Blockade in COVID-19: The Ace of Spades?
por: Agarwal, Krishna A., et al.
Publicado: (2021)

The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19
por: Bellis, Alessandro, et al.
Publicado: (2020)

TranslatiOnal Registry for CardiomyopatHies (TORCH) – rationale and first results
por: Seyler, Claudia, et al.
Publicado: (2017)

Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy
por: Farrant, John, et al.
Publicado: (2023)

Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
por: Bhatt, Deepak L., et al.
Publicado: (2017)

Heart failure prevalence in the general population: SOBOTA‐HF study rationale and design
por: Lainscak, Mitja, et al.
Publicado: (2019)

Regional management of worsening heart failure: rationale and design of the CHAIN‐HF registry
por: Shakoor, Abdul, et al.
Publicado: (2023)

Sacubitril/valsartan for cardioprotection in breast cancer (MAINSTREAM): design and rationale of the randomized trial
por: Tajstra, Mateusz, et al.
Publicado: (2023)

Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease
por: Sorbets, Emmanuel, et al.
Publicado: (2017)

Rationale and design of the EPCHF trial: the early palliative care in heart failure trial (EPCHF)
por: Becher, Marc Ulrich, et al.
Publicado: (2021)

Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study
por: Dauw, Jeroen, et al.
Publicado: (2021)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Rationale and study design of intravenous loop diuretic administration in acute heart failure: DIUR‐AHF
por: Palazzuoli, Alberto, et al.
Publicado: (2017)

Rationale and design of the EU‐CERT‐ICD prospective study: comparative effectiveness of prophylactic ICD implantation
por: Zabel, Markus, et al.
Publicado: (2018)

Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial
por: Morrow, Andrew J, et al.
Publicado: (2020)

Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure
por: Abraham, William T., et al.
Publicado: (2019)

Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)
por: Ambrosy, Andrew P., et al.
Publicado: (2021)

Rationale and design of the AMULET study: A new Model of telemedical care in patients with heart failure
por: Krzesiński, Paweł, et al.
Publicado: (2021)

Rationale and Study Design of the Withdrawal of Spironolactone for Heart Failure with Improved Left Ventricular Ejection Fraction
por: Hyun, Junho, et al.
Publicado: (2021)

Rationale and design of the randomized multicentre His Optimized Pacing Evaluated for Heart Failure (HOPE‐HF) trial
por: Keene, Daniel, et al.
Publicado: (2018)

Rationale and design for ENHANCE CRT: QLV implant strategy for non‐left bundle branch block patients
por: Singh, Jagmeet P., et al.
Publicado: (2018)

Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study
por: Bhatt, Deepak L., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9oe6l9jmjbmov225j6fefi1dh3